Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2017

Open Access 01-12-2017 | Study protocol

The WE-Study: does botulinum toxin A make walking easier in children with cerebral palsy?: Study protocol for a randomized controlled trial

Authors: Siri Merete Brændvik, Karin Roeleveld, Guro Lillemoen Andersen, Anne Elisabeth Ross Raftemo, Kjersti Ramstad, Jasmina Majkic-Tajsic, Torarin Lamvik, Bendik Lund, Turid Follestad, Torstein Vik

Published in: Trials | Issue 1/2017

Login to get access

Abstract

Background

Intramuscular injections of botulinum toxin A (BoNT-A) have been a cornerstone in the treatment of spasticity for the last 20 years. In Norway, the treatment is now offered to two out of three children with spastic cerebral palsy (CP). However, despite its common use, the evidence for its functional effects is limited and inconclusive. The objective of this study is to determine whether BoNT-A makes walking easier in children with CP. We hypothesize that injections with BoNT-A in the calf muscles will reduce energy cost during walking, improve walking capacity, increase habitual physical activity, reduce pain and improve self-perceived performance and satisfaction.

Methods/design

This randomized, double-blinded, placebo-controlled, multicenter trial is conducted in a clinical setting involving three health regions in Norway. Ninety-six children with spastic CP, referred for single-level injections with BoNT-A in the calf muscles, will be invited to participate. Those who are enrolled will be randomized to receive either injections with BoNT-A (Botox®) or 0.9% saline in the calf muscles. Stratification according to age and study center will be made. The allocation ratio will be 1:1. Main inclusion criteria are (1) age 4 − 17.5 years, (2) Gross Motor Function Classification System levels I and II, (3) no BoNT-A injections in the lower limbs during the past 6 months and (4) no orthopedic surgery to the lower limbs during the past 2 years. The outcome measures will be made at baseline and 4, 12 (primary endpoint) and 24 weeks after injections. Primary outcome is change in energy cost during walking. Secondary outcomes are change in walking capacity, change in activity, perceived change in performance and satisfaction in mobility tasks, and pain. The primary analysis will use a linear mixed model to test for difference in change in the outcome measures between the groups. The study is approved by the Regional Ethical Committee and The Norwegian Medicines Agency. Recruitment started in September 2015.

Discussion

The evaluation of effect is comprehensive and includes objective standardized tests and measures on both impairment and activity level. Results are to be expected by spring 2019.

Trial registration

ClinicalTrials.gov, NCT02546999. Registered on 9 September 2015.
Appendix
Available only for authorised users
Literature
1.
Graham HK, Selber P. Musculoskeletal aspects of cerebral palsy. J Bone Joint Surg (Br). 2003;85-B(2):157–66.CrossRef
2.
Andersen GL, Irgens LM, Haagaas I, Skranes JS, Meberg AE, Vik T. Cerebral palsy in Norway: prevalence, subtypes and severity. Eur J Paediatr Neurol. 2008;12(1):4–13.CrossRefPubMed
3.
Dallmeijer AJ, Brehm MA. Physical strain of comfortable walking in children with mild cerebral palsy. Disabil Rehabil. 2011;33(15-16):1351–7.CrossRefPubMed
4.
Saether R, Helbostad JL, Adde L, Braendvik S, Lydersen S, Vik T. Gait characteristics in children and adolescents with cerebral palsy assessed with a trunk-worn accelerometer. Res Dev Disabil. 2014;35(7):1773–81.CrossRefPubMed
5.
Norman JF, Bossman S, Gardner P, Moen C. Comparison of the energy expenditure index and oxygen consumption index during self-paced walking in children with spastic diplegia cerebral palsy and children without physical disabilities. Pediatr Phys Ther. 2004;16(4):206–11.CrossRefPubMed
6.
Johnston TE, Moore SE, Quinn LT, Smith BT. Energy cost of walking in children with cerebral palsy: relation to the Gross Motor Function Classification System. Dev Med Child Neurol. 2004;46(1):34–8.CrossRefPubMed
7.
Kerr C, McDowell BC, Parkes J, Stevenson M, Cosgrove AP. Age-related changes in energy efficiency of gait, activity, and participation in children with cerebral palsy. Dev Med Child Neurol. 2011;53(1):61–7.CrossRefPubMed
8.
Brunton LK, Rice CL. Fatigue in cerebral palsy: a critical review. Dev Neurorehabil. 2012;15(1):54–62.CrossRefPubMed
9.
Dickinson HO, Parkinson KN, Ravens-Sieberer U, Schirripa G, Thyen U, Arnaud C, et al. Self-reported quality of life of 8–12-year-old children with cerebral palsy: a cross-sectional European study. Lancet. 2007;369(9580):2171–8.CrossRefPubMed
10.
Ramstad K, Jahnsen R, Skjeldal OH, Diseth TH. Characteristics of recurrent musculoskeletal pain in children with cerebral palsy aged 8 to 18 years. Dev Med Child Neurol. 2011;53(11):1013–8.CrossRefPubMed
11.
Maher CA, Williams MT, Olds T, Lane AE. Physical and sedentary activity in adolescents with cerebral palsy. Dev Med Child Neurol. 2007;49(6):450–7.CrossRefPubMed
12.
Lance JW. Pathophysiology of spasticity and clinical experience with baclofen. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publisher; 1980. p. 185–220.
13.
Elkamil AI, Andersen GL, Skranes J, Lamvik T, Vik T. Botulinum neurotoxin treatment in children with cerebral palsy: a population-based study in Norway. Eur J Paediatr Neurol. 2012;16(5):522–7.CrossRefPubMed
14.
Strobl W, Theologis T, Brunner R, Kocer S, Viehweger E, Pascual-Pascual I, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins. 2015;7(5):1629–48.CrossRefPubMedPubMedCentral
15.
Bjornson K, Hays R, Graubert C, Price R, Won F, McLaughlin JF, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics. 2007;120(1):49–58.CrossRefPubMedPubMedCentral
16.
Lukban MB, Rosales RL, Dressler D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J Neural Transm. 2009;116(3):319–31.CrossRefPubMed
17.
Narayanan UG. Management of children with ambulatory cerebral palsy: an evidence-based review. J Pediatr Orthop. 2012;32 Suppl 2:172–81.CrossRef
18.
Garcia Salazar LF, dos Santos GL, Pavao SL, Rocha NA, de Russo TL. Intrinsic properties and functional changes in spastic muscle after application of BTX-A in children with cerebral palsy: systematic review. Dev Neurorehabil. 2015;18(1):1–14.CrossRefPubMed
19.
Ryll U, Bastiaenen C, De Bie R, Staal B. Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a systematic review. Dev Med Child Neurol. 2011;53(3):210–6.CrossRefPubMed
20.
Moore AP, Ade-Hall RA, Smith CT, Rosenbloom L, Walsh HP, Mohamed K, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology. 2008;71(2):122–8.CrossRefPubMed
21.
Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.CrossRefPubMedPubMedCentral
22.
Rosenbaum PL, Palisano RJ, Bartlett DJ, Galuppi BE, Russell DJ. Development of the Gross Motor Function Classification System for cerebral palsy. Dev Med Child Neurol. 2008;50(4):249–53.CrossRefPubMed
23.
Koog YH, Min BI. Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review. Clin Rehabil. 2010;24(8):685–700.CrossRefPubMed
24.
Pascual-Pascual SI, Pascual-Castroviejo I, Ruiz PJ. Treating spastic equinus foot from cerebral palsy with botulinum toxin type A: what factors influence the results?: an analysis of 189 consecutive cases. Am J Phys Med Rehabil. 2011;90(7):554–63.CrossRefPubMed
25.
Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al. The updated European Consensus 2009 on the use of botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14(1):45–66.CrossRefPubMed
26.
Love SC, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:9–37.CrossRefPubMed
27.
28.
Gracies JM, Burke K, Clegg NJ, Browne R, Rushing C, Fehlings D, et al. Reliability of the Tardieu Scale for assessing spasticity in children with cerebral palsy. Arch Phys Med Rehabil. 2010;91(3):421–8.CrossRefPubMed
29.
Brehm MA, Becher J, Harlaar J. Reproducibility evaluation of gross and net walking efficiency in children with cerebral palsy. Dev Med Child Neurol. 2007;49(1):45–8.CrossRefPubMed
30.
McDowell BC, Kerr C, Parkes J, Cosgrove A. Validity of a 1 minute walk test for children with cerebral palsy. Dev Med Child Neurol. 2005;47(11):744–8.CrossRefPubMed
31.
Fragala-Pinkham M, O’Neil ME, Lennon N, Forman JL, Trost SG. Validity of the OMNI Rating of Perceived Exertion scale for children and adolescents with cerebral palsy. Dev Med Child Neurol. 2015;57(8):748–53.CrossRefPubMed
32.
Gorter JW, Noorduyn SG, Obeid J, Timmons BW. Accelerometry: a feasible method to quantify physical activity in ambulatory and nonambulatory adolescents with cerebral palsy. Int J Pediatr. 2012;2012:329284.CrossRefPubMedPubMedCentral
33.
Mitchell LE, Ziviani J, Oftedal S, Boyd RN. A systematic review of the clinimetric properties of measures of habitual physical activity in primary school aged children with cerebral palsy. Res Dev Disabil. 2013;34(8):2419–32.CrossRefPubMed
34.
Kjeken I, Slatkowsky-Christensen B, Kvien TK, Uhlig T. Norwegian version of the Canadian Occupational Performance Measure in patients with hand osteoarthritis: validity, responsiveness, and feasibility. Arthritis Rheum. 2004;51(5):709–15.CrossRefPubMed
35.
Klepstad P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage. 2002;24(5):517–25.CrossRefPubMed
36.
Selvaag AM, Ruperto N, Asplin L, Rygg M, Landgraf JM, Forre O, et al. The Norwegian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol. 2001;19(4 Suppl 23):S116–20.PubMed
37.
Hicks CL, von Baeyer CL, Spafford PA, van KI, Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain. 2001;93(2):173–83.CrossRefPubMed
38.
Scholtes VA, Becher JG, Comuth A, Dekkers H, Van Dijk L, Dallmeijer AJ. Effectiveness of functional progressive resistance exercise strength training on muscle strength and mobility in children with cerebral palsy: a randomized controlled trial. Dev Med Child Neurol. 2010;52(6):e107–13.CrossRefPubMed
39.
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.CrossRefPubMedPubMedCentral
40.
Hastings-Ison T, Blackburn C, Rawicki B, Fahey M, Simpson P, Baker R, et al. Injection frequency of botulinum toxin A for spastic equinus: a randomized clinical trial. Dev Med Child Neurol. 2015.
41.
Strengthening clinical research in children and young people. Lancet (London, England). 2015;385(9982):2015.
42.
Worlds Health Organization. ICF: International Classification of Functioning, Disability and Health. Genova: World Health Organization; 2001.
43.
Lieber RLRL, Steinman SS, Barash IAIA, Chambers HH. Structural and functional changes in spastic skeletal muscle. Muscle Nerve. 2004;29(5):615–27.CrossRefPubMed
Metadata
Title
The WE-Study: does botulinum toxin A make walking easier in children with cerebral palsy?: Study protocol for a randomized controlled trial
Authors
Siri Merete Brændvik
Karin Roeleveld
Guro Lillemoen Andersen
Anne Elisabeth Ross Raftemo
Kjersti Ramstad
Jasmina Majkic-Tajsic
Torarin Lamvik
Bendik Lund
Turid Follestad
Torstein Vik
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Trials / Issue 1/2017
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-016-1772-8

Other articles of this Issue 1/2017

Trials 1/2017 Go to the issue

Research

Reporting of critical care trial abstracts: a comparison before and after the announcement of CONSORT guideline for abstracts

Study protocol

Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial

Update

COgnitive behavioural therapy versus standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES): statistical and economic analysis plan for a randomised controlled trial

Study protocol

Cognitive Bias Modification for paranoia (CBM-pa): study protocol for a randomised controlled trial

Study protocol

TIGA-CUB – manualised psychoanalytic child psychotherapy versus treatment as usual for children aged 5–11 years with treatment-resistant conduct disorders and their primary carers: study protocol for a randomised controlled feasibility trial

Study protocol

The efficacy and safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean patients with cold hypersensitivity in the hands: study protocol for a pilot, double-blind, randomized, placebo-controlled, parallel-group clinical trial